Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Zavod, Abigail [3 ]
Legedza, Anna [4 ]
Akerman, Sarah C. [5 ]
Sullivan, Maria A. [5 ,6 ]
机构
[1] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, 2213 Elba St,Ste 156,DUMC 3074, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Clin Res, Waltham, MA USA
[4] Alkermes Inc, Biostat, Waltham, MA USA
[5] Alkermes Inc, Med Affairs, Waltham, MA USA
[6] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE | 2021年 / 47卷 / 06期
关键词
Antagonist; maintenance; opioid discontinuation; partial agonist; substance use; INPATIENT;
D O I
10.1080/00952990.2021.1969659
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. Objectives To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. Methods We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). Results The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Conclusion Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
引用
收藏
页码:753 / 759
页数:7
相关论文
共 50 条
  • [41] Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use
    Nunes, Edward V.
    Comer, Sandra D.
    Lofwall, Michelle R.
    Walsh, Sharon L.
    Peterson, Stefan
    Tiberg, Fredrik
    Hjelmstrom, Peter
    Budilovsky-Kelley, Natalie R.
    JAMA NETWORK OPEN, 2024, 7 (06) : e2417377
  • [42] An Emulated Trial of Buprenorphine-Naloxone Versus Extended-Release Naltrexone Following Medically Managed Opioid Withdrawal
    Larochelle, Marc
    Yan, Shapei
    Christine, Paul
    Hsu, Heather
    Bovell-Ammon, Benjamin
    Puppala, Radhika
    Bernson, Dana
    Liebschutz, Jane
    Walley, Alexander
    Novo, Patricia
    Lee, Joshua
    Rotrosen, John
    Lodi, Sara
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [43] Body Mass Index as a Predictor of Extended-Release Naltrexone Treatment Retention in Individuals With Opioid Use Disorder
    Li, Xinyi
    Langleben, Daniel
    Lynch, Kevin
    Wang, Gene-Jack
    Wiers, Corinde E.
    Shi, Zhenhao
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 416 - 416
  • [44] The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
    Parchinski, Kaley
    Di Paola, Angela
    Wilson, Allison P.
    Springer, Sandra A.
    DRUG AND ALCOHOL DEPENDENCE REPORTS, 2023, 7
  • [45] Extending the Youth Opioid Recovery Support (YORS) Intervention With Patient Choice of Extended-Release Naltrexone or Extended-Release Buprenorphine
    Fishman, Marc
    Selby, Victoria
    Wildberger, Jared
    Lavorato, Luciana
    Thomas, Julia
    Moody, Stanley
    Stidham, Jennifer
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 261 - 262
  • [46] HEALTHCARE RESOURCE UTILIZATION (HRU) ASSOCIATED WITH EXTENDED- RELEASE NALTREXONE (XR-NTX) COMPARED WITH OTHER TREATMENTS IN PUBLICLY INSURED PATIENTS WITH OPIOID USE DISORDER (OUD)
    Haider, B. A.
    Parthan, A.
    Liu, J.
    Niu, X.
    Li-McLeod, J.
    Fratantonio, J.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2020, 23 : S213 - S213
  • [47] Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder
    Lai, Miao
    Bowman, Justin
    Charles, Jasmin
    Smid, Marcela C.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (03) : 342 - 345
  • [48] Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder
    Mitchell, Shannon Gwin
    Fletcher, Jesse B.
    Monico, Laura B.
    Gryczynski, Jan
    Fishman, Marc J.
    O'Grady, Kevin E.
    Schwartz, Robert P.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 163
  • [49] Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting
    Berk, Justin
    del Pozo, Brandon
    Rich, Josiah D.
    Lee, Joshua D.
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : 396 - 398
  • [50] Optimizing opioid use disorder treatment with naltrexone or buprenorphine
    Rudolph, Kara E.
    Diaz, Ivan
    Luo, Sean X.
    Rotrosen, John
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228